ArriVent BioPharma (AVBP) Assets Average (2024 - 2026)
ArriVent BioPharma (AVBP) posted Assets Average of $341.2 million for Q1 2026, up 3.45% sequentially from $329.9 million in Q4 2025, and up 39.15% YoY from $245.2 million in Q1 2025.
ArriVent BioPharma (AVBP) Assets Average (2024 - 2026) Analysis & Trends
ArriVent BioPharma has reported Assets Average for 3 years, with the latest figure at $341.2 million in Q1 2026.
- Quarterly Assets Average rose 39.15% year-over-year to $341.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $341.2 million (up 39.15% YoY) and the FY2025 annual result came in at $304.1 million, up 38.83% from the prior year.
- Assets Average rose to $341.2 million in Q1 2026 per AVBP's latest filing, from $329.9 million in the prior quarter.
- Over five years, Assets Average peaked at $341.2 million in Q1 2026 and troughed at $242.5 million in Q2 2025.
- A 3-year average of $289.5 million and a median of $298.0 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2025 and 2026: Assets Average dropped 23.82% in 2025, then jumped 39.15% in 2026.
- Over 3 years, Assets Average stood at $283.8 million in 2024, then rose by 16.22% to $329.9 million in 2025, then grew by 3.45% to $341.2 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $341.2 million, $329.9 million, and $298.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 372.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 372.01 Mn |
| Mar 31, 2026 | 341.23 Mn |
| Dec 31, 2025 | 329.86 Mn |
| Sep 30, 2025 | 298.03 Mn |
| Jun 30, 2025 | 242.50 Mn |
| Mar 31, 2025 | 245.22 Mn |
| Dec 31, 2024 | 283.83 Mn |
| Sep 30, 2024 | 300.78 Mn |
| Jun 30, 2024 | 318.35 Mn |
| Mar 31, 2024 | 245.47 Mn |